Johnson & Johnson remains a Buy for its stability and consistent dividends, despite short-term price fluctuations and modest ...

Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...

These companies have track records of success, increasing dividends, and fantastic growth prospects, making them all ideal ...

NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf ...

Among the Dow Jones Industrial Average's 30 components, there are two historically cheap brand-name companies, as well as a ...

Learn how holding Realty Income as the largest position in your $10,000 dividend portfolio can reduce risk and maximize ...

Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...

Southfield-based PharmaCo Inc. — a cannabis company linked to a bribery scheme to Michigan’s then-top marijuana regulator ...

Bryan Johnson, the founder of Braintree and subject of a new Netflix doc, is on a quest for remarkable longevity.

Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia gravis.

Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...